Physician profile
Ryan Mopal
NPI 1801673587
$841.17
in general payments reported to CMS, 2019-2025
9 companies · $731 in 2025
The $731 reported for 2025 was more than what 82% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $257.13 | 2025 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.09 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $148.22 | 2025 | |
| Ucb, INC. | $54.69 | 2023 | Cimzia |
| Lilly USA, LLC | $49.49 | 2025 | Mounjaro, Zepbound |
| Viatris Specialty LLC | $43.57 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $32.27 | 2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $23.56 | 2023 | Ultomiris |
| Novo Nordisk INC | $15.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.